Literature DB >> 9096660

Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma.

R Dahiya1, J McCarville, W Hu, C Lee, R M Chui, G Kaur, G Deng.   

Abstract

Identification of loss of heterozygosity on specific genetic loci is crucial for understanding the pathogenesis of prostate cancer at the molecular level. This is especially important because the deleted regions may contain putative tumor suppressor genes. Chromosome 3p loss appears to be frequently associated with various epithelial cancers. To our knowledge, there is no report on loss of heterozygosity (LOH) of chromosome 3 in human prostate cancer. The present study was designed to investigate the LOH on chromosome 3p in microdissected samples of delineated regions of normal and invasive carcinoma areas of prostatic epithelium from the same tumor sections. For this purpose, DNA was extracted from microdissected normal and tumor cells of 38 prostate cancers, amplified by PCR and analyzed for LOH on chromosome 3p using 6 different polymorphic DNA markers (D3S1560, THRB, D3S647, D3S1298, D3S1228 and D3S1296). Our results suggest that LOH was identified in 34 of 38 cases (89%) with at least one marker. Twelve of 30 informative cases showed LOH at D3S1560; 18 of 22 informative cases showed loss at THRB; 20 of 38 informative cases showed deletion at D3S647; 16 of 38 informative cases showed loss at D3S1298; 12 of 34 informative cases showed LOH at D3S1228; and 6 of 34 informative cases showed LOH at D3S1296 regions. Our results suggest that the LOH is on the 3p24-26 and 3p22-12 regions of the short arm of chromosome 3, indicating 2 discrete areas of deletion on chromosome 3p. The deletion at 3p24-26 and 3p22-12 was not related to the stage or grade of the tumor.

Entities:  

Mesh:

Year:  1997        PMID: 9096660     DOI: 10.1002/(sici)1097-0215(19970328)71:1<20::aid-ijc5>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer patients.

Authors:  V Balachandar; B Lakshman Kumar; K Sasikala; P Manikantan; R Sangeetha; S Mohana Devi
Journal:  J Zhejiang Univ Sci B       Date:  2007-09       Impact factor: 3.066

2.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Authors:  J C Alers; P J Krijtenburg; A N Vis; R F Hoedemaeker; M F Wildhagen; W C Hop; T T van Der Kwast; F H Schröder; H J Tanke; H van Dekken
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer.

Authors:  C Jerónimo; R Henrique; J Oliveira; F Lobo; I Pais; M R Teixeira; C Lopes
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

4.  Hereditary prostate cancer in Finland: fine-mapping validates 3p26 as a major predisposition locus.

Authors:  Annika Rökman; Agnes B Baffoe-Bonnie; Elizabeth Gillanders; Henna Fredriksson; Ville Autio; Tarja Ikonen; Kenneth D Gibbs; Marypat Jones; Derek Gildea; Diane Freas-Lutz; Carol Markey; Mika P Matikainen; Pasi A Koivisto; Teuvo L J Tammela; Olli P Kallioniemi; Jeffrey Trent; Joan E Bailey-Wilson; Johanna Schleutker
Journal:  Hum Genet       Date:  2004-11-11       Impact factor: 4.132

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.